PF-4708671

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

20 publications

PF-4708671 Chemical Structure

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 107 In stock
USD 147 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PF-4708671 has been cited by 20 publications

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXWTWM2OD1yLkiyNFI1KM7:TR?= MoPUV2FPT0WU
UACC-893 NUfHTmhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLPRW9KSzVyPUWuNVk5QDZizszN M1yxTHNCVkeHUh?=
A427 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXOVWh{UUN3ME21MlczPTZ5IN88US=> MWDTRW5ITVJ?
OCUB-M MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnYTWM2OD14Lk[2NVAzKM7:TR?= NXnhPZY4W0GQR1XS
SW684 NES4NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITCN5JKSzVyPUeuOVIzPjhizszN MXzTRW5ITVJ?
SK-LMS-1 M2SxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\DTWM2OD17LkCxN|AzKM7:TR?= MkjLV2FPT0WU
CP50-MEL-B MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTlwM{C0NVkh|ryP MXPTRW5ITVJ?
NCI-H1651 M3G3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLHXFFwUUN3ME2xNE4xOjd4IN88US=> M2TOSnNCVkeHUh?=
ABC-1 NULP[IdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFyLkGwN|ch|ryP M3LUUHNCVkeHUh?=
OE19 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFyLkG3N|Mh|ryP NHPJU3NUSU6JRWK=
DSH1 M{HlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M373XmlEPTB;MUCuPFg4QSEQvF2= NV3hT4pQW0GQR1XS
SW13 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7wTWM2OD1zMT65N|E6KM7:TR?= MYDTRW5ITVJ?
MDA-MB-453 NIXFRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[3SmpKSzVyPUGyMlE3ODNizszN MontV2FPT0WU
647-V NIX1[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF{LkO1PFIh|ryP MVTTRW5ITVJ?
NCI-H2342 NX;O[pR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTZblZGUUN3ME2xNk4{QTl3IN88US=> MUjTRW5ITVJ?
LB2241-RCC M{fKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILhRVJKSzVyPUGyMlU4PzlizszN NF:xN3JUSU6JRWK=
UACC-257 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nn[mlEPTB;MUOuOFQ2OyEQvF2= NIr5fmNUSU6JRWK=
NCI-H661 M4LL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTvTWM2OD1zMz62OFQ6KM7:TR?= M1\QS3NCVkeHUh?=
FADU M1PqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfjepdKSzVyPUGzMlY6QTJizszN NVrGVYtJW0GQR1XS
A2780 M{[zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXoXphKSzVyPUGzMlgxPDFizszN NV;5ZZFEW0GQR1XS
NCI-H1793 NIXGeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TXcWlEPTB;MUSuOFA5PSEQvF2= NV;NNFJbW0GQR1XS
TE-8 NWXQbFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjMWI1WUUN3ME2xOU4{PDZ3IN88US=> MoOxV2FPT0WU
HGC-27 NGXENoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvydVJKSzVyPUG2MlE3PDRizszN NG\sboNUSU6JRWK=
MMAC-SF M3nKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TwNGlEPTB;MUeuN|czPyEQvF2= M{\kZXNCVkeHUh?=
Calu-6 NFz1dG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPTTWM2OD1zOD6xOVE{KM7:TR?= NIHqW|BUSU6JRWK=
HUTU-80 NIO0fXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLXWIY{UUN3ME2xPE4{QTV7IN88US=> M2fXeHNCVkeHUh?=
SAS M4DjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF6Lk[0OVUh|ryP NYP5OGpWW0GQR1XS
IST-MES1 NWjySlRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTsTWM2OD1zOD62OVA5KM7:TR?= M33lS3NCVkeHUh?=
C3A M3;jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF6Lke5NVkh|ryP MWDTRW5ITVJ?
ES3 M3LUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i0PWlEPTB;MUiuPFM3PCEQvF2= NXzSSmJuW0GQR1XS
HSC-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rEVGlEPTB;MUmuOlU1OSEQvF2= M4\2TXNCVkeHUh?=
T47D MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHGTWM2OD1{MD6xOFg2KM7:TR?= M2TMVXNCVkeHUh?=
EW-7 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm0TWM2OD1{MD64OVg5KM7:TR?= MXXTRW5ITVJ?
LN-405 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSzTWM2OD1{MD64PVY2KM7:TR?= NWjOUFJNW0GQR1XS
U031 NVL0T4RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnQ[WlKSzVyPUKxMlQ5ODJizszN NYjsXnBnW0GQR1XS
A549 M1yxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvEW4RzUUN3ME2yNU45PDlzIN88US=> MlHGV2FPT0WU
RMG-I NILIZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jjTWlEPTB;MkKuNlY3QCEQvF2= NUL0OI9wW0GQR1XS
BT-474 NF\lZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnYSlVLUUN3ME2yNk43PTVzIN88US=> MU\TRW5ITVJ?
NB69 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\MeXRxUUN3ME2yN{4yPTJizszN NUmxZplTW0GQR1XS
NB7 NUjzWWk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPETWM2OD1{ND6xPFgh|ryP NYizSYp{W0GQR1XS
HCC1569 NVv2dnpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;kb45KSzVyPUK0MlYyOjVizszN M2q0bnNCVkeHUh?=
MEL-JUSO MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[xN4tKSzVyPUK0MlY6ODhizszN M3H5enNCVkeHUh?=
MDA-MB-175-VII M2jw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTzTWM2OD1{NT6yOVE4KM7:TR?= NY\MfGJUW0GQR1XS
HCC1419 NEnWRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ3Lk[wNFMh|ryP Ml;TV2FPT0WU
Ca9-22 NHvpNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH1TWM2OD1{NT62OFMzKM7:TR?= NVvTO|RiW0GQR1XS
KGN M1fR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;zU5dKSzVyPUK1Mlc2PDdizszN MmnoV2FPT0WU
LB373-MEL-D MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rOSGlEPTB;Mk[uNVk{QCEQvF2= NInBfoVUSU6JRWK=
NCI-H1755 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MliyTWM2OD1{Nj64PFQyKM7:TR?= M4LNU3NCVkeHUh?=
D-423MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmeyTWM2OD1{Nz6wO|E2KM7:TR?= NFjPW|hUSU6JRWK=
DK-MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi3Tlg1UUN3ME2yPE44QDR4IN88US=> NFj5SnpUSU6JRWK=
NCI-H1623 M{f3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Lp[mlEPTB;MkiuPFM1OiEQvF2= MUjTRW5ITVJ?
KU-19-19 NUPFNJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJ6Lkm5OUDPxE1? NXnSWpBTW0GQR1XS
C-33-A M{[3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DDVmlEPTB;MkmuNlE6QCEQvF2= NFvMUJFUSU6JRWK=
SCC-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jiVmlEPTB;M{CuN|M2PCEQvF2= MX\TRW5ITVJ?
MG-63 NIWxPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nUd2lEPTB;M{CuOVk6PCEQvF2= M3fBUnNCVkeHUh?=
LNCaP-Clone-FGC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HyfGlEPTB;M{GuOFkzOSEQvF2= M{LxcHNCVkeHUh?=
CAPAN-1 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTNzLkWyPFYh|ryP MlPGV2FPT0WU
GI-ME-N NVrMd|hTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn1RpBkUUN3ME2zNU42OzV|IN88US=> NVGyNpA1W0GQR1XS
RERF-LC-MS NXn6SotmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXSdnBKSzVyPUOyMlY4PDdizszN NVTQb2h2W0GQR1XS
KLE NGPJPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTN|LkSzN|Qh|ryP M{H5OnNCVkeHUh?=
KNS-81-FD NFPzTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnaTWM2OD1|Mz61NFA5KM7:TR?= MVXTRW5ITVJ?
DOK MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jMVWlEPTB;M{SuOlYyOiEQvF2= NWLHVWRFW0GQR1XS
ACHN NVTHOlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ewUGlEPTB;M{WuNVU5QCEQvF2= NVSwO3REW0GQR1XS
KYSE-520 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;aWGxKSzVyPUO1MlI{PjFizszN NUf1XHFPW0GQR1XS
SBC-5 NIXP[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPyTWM2OD1|NT61NVE3KM7:TR?= MlTKV2FPT0WU
NCI-H28 M4Czbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfDdVJKSzVyPUO1MlY3QTVizszN M{fQNHNCVkeHUh?=
ES7 NWfYXFBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3mT2FMUUN3ME2zOk4zOjR7IN88US=> NHLBUoFUSU6JRWK=
A172 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN4LkSxPFch|ryP MnfHV2FPT0WU
UM-UC-3 M2rnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nONGlEPTB;M{euPFc1PiEQvF2= NFK0bllUSU6JRWK=
LXF-289 NWfUeW91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3HWIE4UUN3ME2zPE4xODR5IN88US=> MXfTRW5ITVJ?
KP-4 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTN6LkS3N|kh|ryP NYH5UWxrW0GQR1XS
TE-1 NXviXmhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfxWm5KSzVyPUO5MlY2QDlizszN MkHTV2FPT0WU
G-402 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvQbWJKSzVyPUSwMlA3OSEQvF2= Mmf5V2FPT0WU
786-0 Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS5OVJKSzVyPUSwMlkxQTZizszN MX3TRW5ITVJ?
K5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LafWlEPTB;NEGuN|Y5PiEQvF2= MYnTRW5ITVJ?
SK-N-DZ MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTRzLkO4NlMh|ryP MmXmV2FPT0WU
OVCAR-4 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnRR3hiUUN3ME20NU44PTZ6IN88US=> MWTTRW5ITVJ?
T84 M3:xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTBcXBlUUN3ME20Nk4yOjZ|IN88US=> MnrsV2FPT0WU
GCIY NWPlPWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3yxPWlEPTB;NEOuNFgxOyEQvF2= NHXKc41USU6JRWK=
BB49-HNC M{PQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWyTFY6UUN3ME20N{4{OzR6IN88US=> M3XCdnNCVkeHUh?=
SNU-C2B M4HCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXoWXBKSzVyPUSzMlY1OzZizszN MkXyV2FPT0WU
TE-6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DqUGlEPTB;NEOuPFg6PCEQvF2= MmPLV2FPT0WU
23132-87 NEHneXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CwdmlEPTB;NESuNlk4QCEQvF2= MnfEV2FPT0WU
DMS-53 NHTjR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrnSXF1UUN3ME20OE4{Ozh2IN88US=> MVzTRW5ITVJ?
ONS-76 Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTR2Lke2OlEh|ryP NVfldVhPW0GQR1XS
DMS-273 NEnXZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjFRo5uUUN3ME20OE46PDNizszN NUXaSploW0GQR1XS
COLO-824 NH7OenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DQfWlEPTB;NEWuPFc4PSEQvF2= NXrEcY55W0GQR1XS
DMS-114 NVnUW21LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqzTWM2OD12NT64PVI4KM7:TR?= NXXCZW9jW0GQR1XS
YKG-1 NGL1c4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTR4LkCzOVUh|ryP M4PNS3NCVkeHUh?=
RH-18 M3XH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m3b2lEPTB;NE[uN|c{OyEQvF2= NX7lUmhZW0GQR1XS
NCI-H1355 M3W5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TaUWlEPTB;NE[uOlE5KM7:TR?= MVfTRW5ITVJ?
NCI-H2170 NWPuOFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTR5Lke1PFQh|ryP NH;EZo9USU6JRWK=
OC-314 NVn0T49HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR5Lki0O|gh|ryP MlT3V2FPT0WU
NCI-H2030 M2LoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfPWo9DUUN3ME20O{45QTB4IN88US=> M1zuc3NCVkeHUh?=
22RV1 M1rjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDFTWM2OD12Nz65NFE2KM7:TR?= NVuzRYpMW0GQR1XS
G-401 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfVSVJKSzVyPUS4MlQ1OTVizszN M3P2[3NCVkeHUh?=
YAPC NGe2T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\BcJVZUUN3ME20PU45ODd|IN88US=> MUXTRW5ITVJ?
SW1573 NF34Xm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTVyLkK0N|Uh|ryP NYTURVFRW0GQR1XS
COLO-792 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv3VnhKSzVyPUWwMlYzOzdizszN NYHHcGFVW0GQR1XS
KNS-62 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTVyLke1NFgh|ryP MV\TRW5ITVJ?
NB5 NVfKWXg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTVzLkS1NFkh|ryP M3TZW3NCVkeHUh?=
CP66-MEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlryTWM2OD13MT62OFA5KM7:TR?= NVHENIdnW0GQR1XS
CaR-1 NXfFN2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPFTWM2OD13Mj6wOlA3KM7:TR?= M1\YTXNCVkeHUh?=
CAL-54 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{myRWlEPTB;NUKuNVExOiEQvF2= NUjOO5I1W0GQR1XS
8305C M1HnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\nTYtKSzVyPUWyMlMyPSEQvF2= NHrLXmNUSU6JRWK=
Calu-3 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTV{LkO3N|Mh|ryP MVvTRW5ITVJ?
AU565 Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q3VGlEPTB;NUKuOVUxQSEQvF2= NVfnV3dCW0GQR1XS
CW-2 M170dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK0TWM2OD13Mj64OlU1KM7:TR?= NH\0O|RUSU6JRWK=
BEN M{[3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPMTWM2OD13Mz63PFYzKM7:TR?= NUf0ZnZzW0GQR1XS
NCI-H1975 NELKVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLzTWM2OD13Mz64PVY3KM7:TR?= NHTuXIxUSU6JRWK=
HCT-116 M{i5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPUTWM2OD13ND6wN|I4KM7:TR?= NH7NUWxUSU6JRWK=
SH-4 NWX1WXJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTV2LkGzPEDPxE1? MkHMV2FPT0WU
NCI-H1693 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX6TWM2OD13ND6yNVA{KM7:TR?= MkLLV2FPT0WU
BPH-1 M37SPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLs[4VNUUN3ME21OU4zQDl{IN88US=> MlfOV2FPT0WU
CAMA-1 NUiwNpBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PGXGlEPTB;NUWuPFEyPiEQvF2= MmewV2FPT0WU
A388 M3nwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnqNolKSzVyPUW2MlA6QDVizszN M1vmT3NCVkeHUh?=
C2BBe1 M13ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rS[GlEPTB;NU[uNlY{PCEQvF2= MmTOV2FPT0WU
GAMG NXzkN2FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjOeoNKSzVyPUW2MlU6PTVizszN MVHTRW5ITVJ?
MKN28 NFPuNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\PO2V7UUN3ME21Ok45ODF|IN88US=> NYDEPHZVW0GQR1XS
VA-ES-BJ MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrSbFFKSzVyPUW2Mlg4PDVizszN NFOySIFUSU6JRWK=
HuCCT1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7JRmdKSzVyPUW3MlA1QTJizszN NVG3fVJwW0GQR1XS
BFTC-905 NVfUSI4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3kVGNUUUN3ME21O{4zQDl6IN88US=> MlvnV2FPT0WU
LS-123 NFTwN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\YR4FKSzVyPUW3MlU3PjhizszN M1HvWHNCVkeHUh?=
LB996-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrzTWM2OD13OD6wNlg4KM7:TR?= NX[3T5Z[W0GQR1XS
NCI-H1048 NXzRO2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nK[mlEPTB;NUiuNlE5QCEQvF2= NEnnT5BUSU6JRWK=
COR-L105 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HIZ2lEPTB;NUiuO|M{PyEQvF2= M4DwOHNCVkeHUh?=
OVCAR-8 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLPUINKSzVyPUW5MlE4OTZizszN MWLTRW5ITVJ?
SK-N-FI NVLmPHdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nqcmlEPTB;NUmuN|IxPyEQvF2= MYrTRW5ITVJ?
MES-SA MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHvRYRuUUN3ME21PU41PTB7IN88US=> MXXTRW5ITVJ?
SCC-9 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiweIJKSzVyPUW5MlQ4PTNizszN MXHTRW5ITVJ?
EFO-27 NIfkNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTV7Lkm0N{DPxE1? M3LNTXNCVkeHUh?=
GT3TKB M3\0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP1c2YxUUN3ME22NE43ODR6IN88US=> NH3zbZlUSU6JRWK=
HCC38 NF7EeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Xy[mlEPTB;NkGuOFM4QSEQvF2= MnjIV2FPT0WU
MLMA Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTZzLk[xOlMh|ryP MXLTRW5ITVJ?
D-566MG M{TJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTZ|LkWyNlQh|ryP NI\zOXpUSU6JRWK=
SF295 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm1TWM2OD14Mz62OlU2KM7:TR?= NWHPZWFGW0GQR1XS
ES4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLsTWM2OD14ND60O|E6KM7:TR?= NX;USYJIW0GQR1XS
CAKI-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonITWM2OD14ND61O|IyKM7:TR?= MnHwV2FPT0WU
OAW-28 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:wTWM2OD14ND65OlQ4KM7:TR?= NFfUcFFUSU6JRWK=
NCI-H460 NH\BXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jOPGlEPTB;NkWuNFg6PyEQvF2= NFezZlhUSU6JRWK=
JAR MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XDRWlEPTB;NkWuOVUyPiEQvF2= MYrTRW5ITVJ?
SNU-449 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GzU2lEPTB;NkWuO|YyPiEQvF2= MWHTRW5ITVJ?
D-392MG NUKxemNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LHTmlEPTB;NkWuPVQ{PCEQvF2= M4H0NXNCVkeHUh?=
EW-22 NUXsXIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf4bplKSzVyPU[2MlM6PSEQvF2= MWHTRW5ITVJ?
GCT NWfuRno{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\qV4l{UUN3ME22O{4xPDR|IN88US=> MXrTRW5ITVJ?
NOS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjBPXJYUUN3ME22O{43QDZ5IN88US=> M{\wc3NCVkeHUh?=
RH-1 M4HPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzUdnhKSzVyPU[4MlU2PTlizszN M4LjNHNCVkeHUh?=
HuH-7 M4j3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjubZluUUN3ME22PU4yODB{IN88US=> M2TIfnNCVkeHUh?=
NUGC-3 M1XVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDkTWM2OD15MD65OlQ1KM7:TR?= Mof5V2FPT0WU
IST-SL1 MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vXRWlEPTB;N{GuNlMzPCEQvF2= NFrUPIlUSU6JRWK=
SHP-77 MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WxPGlEPTB;N{KuNVE6KM7:TR?= NYrUO|dEW0GQR1XS
SW1116 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTd{LkG0NFch|ryP MVTTRW5ITVJ?
LK-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv2Zo45UUN3ME23Nk45PjF{IN88US=> M{ntS3NCVkeHUh?=
U-2-OS NYnDTFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1GwN2lEPTB;N{OuNVgzQCEQvF2= MUHTRW5ITVJ?
KYSE-150 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTd|Lk[xNVgh|ryP NXzRRotSW0GQR1XS
U251 NHXpVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljvTWM2OD15Mz64NVY5KM7:TR?= M{\SWHNCVkeHUh?=
HT-1080 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTd2LkK1O|Qh|ryP NES2[WNUSU6JRWK=
NCI-H1437 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rZRmlEPTB;N{SuOlMzPiEQvF2= MWrTRW5ITVJ?
HPAF-II MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT0O21zUUN3ME23OE43PDF3IN88US=> MUHTRW5ITVJ?
Becker M1jRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDobo5KSzVyPUe1MlEyODVizszN M3n0S3NCVkeHUh?=
PANC-10-05 NUDLdoNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm4OXVuUUN3ME23OU4zQDZ3IN88US=> M3XXRXNCVkeHUh?=
TYK-nu MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3G[IVKSzVyPUe1MlMyODJizszN NUS2PXdPW0GQR1XS
SKG-IIIa MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\NRXVuUUN3ME23OU4{OzRzIN88US=> MmP5V2FPT0WU
NCI-H1993 MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX1R2ZKSzVyPUe1Mlc{QTdizszN MnnqV2FPT0WU
S-117 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHZTWM2OD15NT63OVUh|ryP NFLKPZVUSU6JRWK=
HuO9 NVvHdVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPLPGRKSzVyPUe2MlAxPDhizszN MUHTRW5ITVJ?
CAL-51 NFXET4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nVV2lEPTB;N{[uNVAxPiEQvF2= M3fGdXNCVkeHUh?=
BT-20 M{DtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrEenRNUUN3ME23Ok4zOTZ6IN88US=> NXvxUm9PW0GQR1XS
LB831-BLC NVe3NGU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu0TWM2OD15Nj6zNlE4KM7:TR?= MXjTRW5ITVJ?
LB1047-RCC NFLRUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTd4Lke2NVkh|ryP MWDTRW5ITVJ?
ES8 M1rJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTd6LkCwO|Mh|ryP MYTTRW5ITVJ?
UMC-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rsWWlEPTB;N{iuNFg5PCEQvF2= MX3TRW5ITVJ?
NCI-H226 NHjTS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTd6LkGzNVUh|ryP NWHQ[pdFW0GQR1XS
IGROV-1 NUjVdJJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon6TWM2OD15OD61OVUh|ryP NF3Ke|ZUSU6JRWK=
BHY NIDhN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTd7LkW5OkDPxE1? MVvTRW5ITVJ?
MKN45 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRThyLkOxO|Qh|ryP NH;0SFJUSU6JRWK=
IA-LM NHvnXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO3b5h4UUN3ME24NE4{PTFzIN88US=> MYjTRW5ITVJ?
WM-115 NUPHSodKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRThzLkSxNVQh|ryP NHjMWGxUSU6JRWK=
VMRC-RCZ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PkXmlEPTB;OEGuOFQzPSEQvF2= MXfTRW5ITVJ?
NCI-H2291 NXyxWZBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjPWpBKSzVyPUixMlY5PDJizszN MkW2V2FPT0WU
MCF7 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPrTWM2OD16Mz6yPFk4KM7:TR?= NFvoWY9USU6JRWK=
639-V MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrGTGdKSzVyPUi0MlYyOjlizszN NYr5d5d1W0GQR1XS
RT4 NI[3UpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTh3LkK0NFMh|ryP MYTTRW5ITVJ?
NCI-H2405 NFPweG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjHTWM2OD16NT6yPVk4KM7:TR?= MUfTRW5ITVJ?
CAL-33 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\TUmZDUUN3ME24OU43OzF3IN88US=> Ml7VV2FPT0WU
BT-549 NH74OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;LTWM2OD16NT65N|gzKM7:TR?= M1fD[HNCVkeHUh?=
HT-1197 NXrlWnBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTh6LkGwO|ch|ryP NE[xVVBUSU6JRWK=
G-361 NYPRbpozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC0TWM2OD16OD6xOFc1KM7:TR?= MVTTRW5ITVJ?
LS-411N NG\jPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTh7LkOzPFgh|ryP MlLMV2FPT0WU
HT-144 NXTybIpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPyTWM2OD16OT61PVkzKM7:TR?= NEXWe3hUSU6JRWK=
DJM-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTh7Lki4OFUh|ryP NHLzOIFUSU6JRWK=
CAL-12T NFvBdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTlyLke4PVUh|ryP NITucFRUSU6JRWK=
MKN7 NG\nU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\zTWM2OD17MT6zOVUyKM7:TR?= MlPtV2FPT0WU
HuP-T3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PBPWlEPTB;OU[uNVAxPCEQvF2= NYL4R2F5W0GQR1XS
SK-MG-1 NWK5VYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLFTWM2OD17Nj6xN|Q5KM7:TR?= MkXMV2FPT0WU
NCI-H2347 NIXiOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjFSodKSzVyPUm4MlExPDJizszN NIHJZoNUSU6JRWK=
SW872 NV\He3R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfXdndKSzVyPUGwNE41PTZizszN Mn7jV2FPT0WU
COLO-829 M3zpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\6VJRKSzVyPUGwNE42PTNizszN MULTRW5ITVJ?
MC-IXC NV3FNGpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFyMD62NVUh|ryP NVjmVpdQW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

28626016 30423811
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A
Smiles CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID